All studies
Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Ngm Biopharmaceuticals Inc.
Enrolment target
45
Start
04 Jul 2023
What is this study about?
" Treatment-emergent AEs characterized by type, frequency, severity (graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study drug", " Objective tumor response (ORR) as per RECIST v1.1"
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (3)
- —France
- —Italy
- —Spain
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.